The medical beauty track has been active for more than half a year. With the increasing attention, some listed companies have begun the road of medical beauty transformation, and Teyi Pharmaceutical is one of them. However, there are a series of problems in the operation of Teyi Pharmaceutical, such as serious decline, insufficient competitiveness of product structure, family management and so on. Can the sudden transformation of medical beauty be recognized by the market?
The beauty of transformational medicine attracts people's attention
19 in may, the special pharmaceutical industry announced that it planned to invest 1 100 million yuan to establish Guangdong temei health technology industry co., ltd (tentative) as the investment and operation platform for the big health industry of the special pharmaceutical industry group, with the development direction as follows: comprehensively lay out the development and investment in the field of medical beauty services; Taking the clinical research on acne and Jinkui Shenqi tablets by Du Xue Pill, a traditional Chinese medicine product of Teyi Pharmaceutical Company, as an opportunity, we will vigorously develop and introduce upstream varieties of medical beauty; Combining the experience and brand advantages of Zhikebao tablets, we will promote the development of healthy consumer goods with the functions of clearing throat and benefiting throat, which are convenient to carry and use; Directly or through industrial funds, M&A funds, etc. Acquisition of related targets of big health industry.
After the announcement, the share price of Teyi Pharmaceutical rose for two consecutive days. Compared with the stock price, the rise of special convertible bonds is even more jaw-dropping, and even there has been a "miracle" of a 45% rise in a single day. On the day of the above announcement, the special convertible bonds opened sharply higher, and then hit 20% of the intraday fuse red line and had to be suspended for 30 minutes; After the resumption of trading, only one transaction of special convertible bonds touched the 30% fuse red line. According to the statistics after the end of trading hours, only five transactions, special convertible bonds rose by 45% in a single day.
Since Aimeike went public in May, last year, 5438+ 10, the Medical Beauty Circuit has experienced wave after wave of climax. 1. Hyaluronic acid Three Musketeers Aimeike, Huaxi Bio, Haohaishengke reached new heights; Then in March of this year, the listing of Betani continued to fuel the medical beauty track. The market value of medical beauty leader Aimeike has exceeded 654.38+03 billion yuan. Betaine has been listed for two months, and its market value has also exceeded 654.38+065.438+000 billion yuan, and its static P/E ratio is 298 times and 202 times respectively.
With the increasing popularity of the concept of medical beauty, listed companies with sudden transformation began to appear in the market. For example, since April this year, Aoyuan Meigu has made frequent moves in transforming the beautiful and healthy business, and successively signed several strategic cooperation agreements, and its share price doubled in less than one month; On April 1 day, Rabbi Blonde announced that it planned to acquire the equity of 4,023,500 yuan of Hanfei Investment, a medical beauty company held by Huaihua Mei Wen, for 238 million yuan. Up to now, the share price has risen by over 190%.